Infanta Leonor University Hospital, Spain  

Autoantibodies As An Indicator Of Poor Prognosis In COVID-19

This study shows that 10% of patients with severe COVID-19 have neutralising antibodies against the cytokine interferon type 1.

Hospital Universitario HM Puerta del Sur, Spain  

Prognostic Implications Of Neutrophil-Lymphocyte Ratio In COVID-19

This study aims to determine whether the neutrophil-to-lymphocyte ratio (NLR) can be useful in the diagnosis and treatment of COVID-19.

HM Hospitals group, Spain  

Risk Score For Predicting In-hospital Mortality In COVID-19

The RIM score, a simple and widely available tool that can help identify patients at risk of fatal COVID-19 outcomes.

Technische Universität München, Germany  


Identifying true markers of protective immunity will allow for the identification of individuals, in particular healthcare personnel working with COVID-19 patients and in other critical areas protected from re-infection.

Strasbourg University Hospital, France.  

Sex Differences In The Evolution Of Neutralizing Antibodies To SARS-CoV-2

This study aims to determine the differences in the evolution of the immune response in the months following SARS-CoV-2 infection in men and women.

Assistance Publique des Hopitaux de Paris, France  

Convalescent plasma therapy and COVID-19

Convalescent plasma with anti-SARS-CoV-2 antibodies appears to be a very promising approach in the context of protracted COVID-19 symptoms in patients unable to mount a specific humoral response to SARS-CoV-2.

Hospital Clínic Barcelona, Spain  

Autoimmune and immune-mediated diseases and symptomatic COVID-19

This study analyses if patients with autoimmune diseases and coronavirus infection have a lower risk of developing severe COVID.

IDIBELL, Spain  


Are you immunosuppressed? Engage this study and help underestand the kinetics of adaptive immunization against COVID-19.

Hospital Clínic Barcelona, Spain  

Developing Therapies Based On The SARS-CoV-2 Cellular Response

This study aims to better understand the functioning of the immune response to SARS CoV-2 in order to propose new treatments based on the body’s cellular response to COVID-19.